Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
1.300
-0.050 (-3.70%)
At close: May 29, 2026, 4:00 PM EDT
1.291
-0.009 (-0.71%)
After-hours: May 29, 2026, 7:48 PM EDT

Dermata Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
5.274.844.313.974.024.4
Research & Development
2.032.938.24.075.653.46
Total Operating Expenses
7.37.7712.518.049.677.86
Operating Income
-7.36-7.77-12.51-8.04-9.67-7.86
Interest Income
0.260.220.230.250.06-0.05
Total Non-Operating Income (Expense)
0.260.220.230.250.06-0.05
Pretax Income
-7.1-7.56-12.29-7.79-9.61-7.9
Net Income
-7.1-7.56-12.29-7.79-9.61-10.46
Net Income Attributable to Preferred Dividends
-----2.56
Net Income to Common
-7.1-7.56-12.29-7.79-9.61-10.46
Shares Outstanding (Basic)
210000
Shares Outstanding (Diluted)
210000
Shares Change (YoY)
550.74%505.46%684.77%323.35%156.86%125.13%
EPS (Basic)
-5.31-8.16-80.32-399.90-2088.00-5832.00
EPS (Diluted)
-5.31-8.16-80.32-399.90-2088.00-5832.00
Shares Outstanding
4.022.660.250.030.010
Free Cash Flow
-8.3-7.76-11.16-6.41-8.83-5.69
Free Cash Flow Per Share
-4.72-8.38-72.97-328.79-1918.62-3176.06
EBITDA
-7.36-7.77-12.51-8.04-9.67-7.86
EBIT
-7.36-7.77-12.51-8.04-9.67-7.86
SEC Filings: 10-K · 10-Q